Status:
COMPLETED
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Lead Sponsor:
Medicure
Collaborating Sponsors:
SCRI Development Innovations, LLC
Conditions:
Myocardial Infarction
Acute Coronary Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous corona...
Eligibility Criteria
Inclusion
- Age ≥18 years of age
- Scheduled to undergo PCI with an FDA, approved or cleared device (stent or procedures such as balloon angioplasty, rotoblation, AngioSculpt, laser atherectomy,etc.) in one or more native coronary target lesions
- Written informed consent
Exclusion
- Primary PCI for STEMI as index procedure
- Prior STEMI within 48 hours before randomization
- Prior PCI within 30 days before randomization
- Planned staged PCI within the subsequent 24 hours after index PCI
- Use of abciximab within 7 days before randomization
- Use of tirofiban or eptifibatide within 12 hours before randomization
- Use of low-molecular weight heparin within 12 hours before randomization
- Use of bivalirudin within 12 hours before randomization
Key Trial Info
Start Date :
April 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2019
Estimated Enrollment :
535 Patients enrolled
Trial Details
Trial ID
NCT01522417
Start Date
April 1 2012
End Date
March 1 2019
Last Update
May 13 2021
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Osceola Regional Medical Center
Kissimmee, Florida, United States, 34741
2
Northside Hospital
St. Petersburg, Florida, United States, 33709
3
Emory University Hospital Midtown
Atlanta, Georgia, United States, 30308
4
Emory University Hospital
Atlanta, Georgia, United States, 30322